Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

As one of the world’s best-selling pharmaceuticals, the approaching expiration of U.S. patents for MSD’s immune-oncology drug ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

The domestic patent for Keytruda, the world’s top-selling medicine by annual sales, is scheduled to expire in 2028. A fierce ...

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...

Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

On the second night of the largest annual European cancer conference, some 100 Merck scientists packed into Champeaux, a classic French restaurant, to break bread and share clinical wisdom. It was ...

The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ...

Samsung Bioepis, a company developing biosimilars and new drugs, announced the interim results of its phase 1 and phase 3 ...